Latest Ratios: P/E Ratio 0.9x · EV/EBITDA N/A · ROE 3.8%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $6M | $6M | $3M |
| Enterprise Value | $6M | $6M | $3M |
| P/E Ratio → | 0.88 | 0.97 | 0.72 |
| P/S Ratio | — | — | — |
| P/B Ratio | 0.03 | 0.03 | 0.01 |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | 0.55 |
| EV / EBIT | — | — | 0.55 |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 3.8% | 3.8% | 2.1% |
| ROA | 3.6% | 3.6% | 2.0% |
| ROIC | -0.3% | -0.3% | — |
| ROCE | -0.4% | -0.4% | -0.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | — | — | — |
| Debt / EBITDA | — | — | — |
| Net Debt / Equity | — | -0.00 | -0.00 |
| Net Debt / EBITDA | — | — | -0.15 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($65427) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 0.89 | 0.89 | 25.28 |
| Quick Ratio | 0.89 | 0.89 | 25.28 |
| Cash Ratio | 0.21 | 0.21 | 21.38 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 100.0% | 103.6% | 138.9% |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $23M | $31M |
Liquidation before merger completion
According to reported financial data, SIMAW trades at a P/E of 0.86 and a P/B of 0.02, metrics that appear artificially low due to the shell company structure rather than reflecting genuine undervaluation or a compelling growth trajectory relative to the broader healthcare investment sector.
The P/B ratio of 0.02 suggests the market is pricing the equity at a significant discount to the trust value, likely reflecting investor skepticism regarding the sponsor's ability to execute a value-accretive merger. These multiples are largely irrelevant for a pre-revenue entity and should not be interpreted as indicators of future earnings potential or operational success.
Based on recent SEC filings, the current ratio has deteriorated from 112.15 in 2024Q3 to 0.79 in 2026Q1, indicating that the company's ability to cover short-term obligations has weakened significantly as the mandatory merger deadline approaches and operating cash reserves are depleted by ongoing administrative expenses.
The rapid decline in the current ratio highlights the structural vulnerability of the entity as it consumes its limited cash balance to fund due diligence and regulatory compliance. Investors should monitor whether the current liquidity level is sufficient to sustain operations through the remainder of the merger window without requiring dilutive financing.
As reported in financial statements, SIMAW's ROIC has trended into negative territory, reaching -0.0% in 2026Q1, which confirms that the entity is currently failing to generate any meaningful return on the capital deployed by the sponsor during the pre-combination phase of the business lifecycle.
The inability to generate positive returns on invested capital is an expected outcome for a shell company, yet the trend suggests that the costs of maintaining the public listing are eroding the value of the initial capital. This metric underscores the necessity of a successful business combination to pivot the company toward a productive, return-generating operational model.
The most commonly misapplied ratio for SIMAW is the Price-to-Earnings (P/E) multiple, which obscures the reality that current net income is driven by non-operating interest income rather than operational performance, rendering it a misleading indicator of the company's true economic value or future earnings power.
Analysts should instead focus on the 'burn rate' and the 'time to expiry' of the merger window, as these metrics provide a more accurate assessment of the company's viability. Relying on P/E ratios for a pre-revenue SPAC ignores the binary nature of the business model and the significant risk of liquidation.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SIMAW stock.
SIM Acquisition Corp. I's current P/E ratio is 0.9x. The historical average is 0.8x. This places it at the 50th percentile of its historical range.
SIM Acquisition Corp. I's return on equity (ROE) is 3.8%. The historical average is 3.0%.
Based on historical data, SIM Acquisition Corp. I is trading at a P/E of 0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.